Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 981-990

  Aguilar Rojas, Arturo ^a   Huerta Reyes, Maira ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cell motility; Cell proliferation; Cytoskeleton; Human gonadotrophin releasing hormone; Human Gonadotrophin releasing hormone receptors

Indexed keywords

BUSERELIN; CETRORELIX; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; TAMOXIFEN;

BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER TISSUE; CARCINOGENESIS; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; EXTRAPITUITARY TISSUE; GROWTH INHIBITION; HORMONE ACTION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION;

GONADOTROPIN-RELEASING HORMONE; GTP-BINDING PROTEINS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION;

EID: 70449448175     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000525     Document Type: Review

References (142)

1. Conn PM, Staley D, Harris C, et al: Mechanism of action of gonadotropin releasing hormone. Annu Rev Physiol 48: 495-513, 1986.
2. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K and Maudsley SR: Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235-275, 2004.
3. Kakar SS, Musgrove LC, Devor DC, Sellers JC and Neill JD: Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189: 289-295, 1992.
4. Pierce JG and Parsons TF: Glycoprotein hormones: structure and function. Annu Rev Biochem 50: 465-495, 1981.
5. Stojilkovic SS, Reinhart J and Catt KJ: Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 15: 462-499, 1994.
6. Ulloa-Aguirre A, Janovick JA, Miranda AL and Conn PM: G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. ACS Chem Biol 1: 631-638, 2006.
7. Harris D, Reiss N and Naor Z: Differential activation of protein kinase C delta and epsilon gene expression by gonadotropin-releasing hormone in alphaT3-1 cells. Autoregulation by protein kinase C. J Biol Chem 272: 13534-13540, 1997.
8. Naor Z, Benard O and Seger R: Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 11: 91-99, 2000.
9. Schaeffer HJ and Weber MJ: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999.
10. Chen Z, Gibson TB, Robinson F, et al: MAP kinases. Chem Rev 101: 2449-2476, 2001.
11. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
12. Krens SF, Spaink HP and Snaar-Jagalska BE: Functions of the MAPK family in vertebrate-development. FEBS Lett 580: 4984-4990, 2006.
13. Segal RA and Greenberg ME: Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19: 463-489, 1996.
14. Cobb MH and Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 270: 14843-14846, 1995.
15. Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14536, 1993.
16. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
17. Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R and Naor Z: Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 252: 184-190, 2006.
18. Mitchell R, Sim PJ, Leslie T, Johnson MS and Thomson FJ: Activation of MAP kinase associated with the priming effect of LHRH. J Endocrinol 140: R15-R18, 1994.
19. Haisenleder DJ, Cox ME, Parsons SJ and Marshall JC: Gonadotropin-releasing hormone pulses are required to maintain activation of mitogen-activated protein kinase: role in stimulation of gonadotrope gene expression. Endocrinology 139: 3104-3111, 1998.
20. Sim PJ, Wolbers WB and Mitchell R: Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin-sensitive G protein. Mol Cell Endocrinol 112: 257-263, 1995.
21. Sundaresan S, Colin IM, Pestell RG and Jameson JL: Stimulation of mitogenactivated protein kinase by gonadotropin releasing hormone: evidence for the involvement of protein kinase C. Endocrinology 137: 304-311, 1996.
22. Reiss N, Llevi LN, Shacham S, Harris D, Seger R and Naor Z: Mechanism of mitogen-activated protein kinase activation by gonadotropin-releasing hormone in the pituitary of alphaT3-1 cell line: differential roles of calcium and protein kinase C. Endocrinology 138: 1673-1682, 1997.
23. Lin X and Conn PM: Transcriptional activation of gonadotropin-releasing hormone (GnRH) receptor gene by GnRH: involvement of multiple signal transduction pathways. Endocrinology 140: 358-364, 1999.
24. Roberson MS, Misra-Press A, Laurance ME, Stork PJ and Maurer RA: A role for mitogen-activated protein kinase in mediating activation of the glycoprotein hormone alpha-subunit promoter by gonadotropin releasing hormone. Mol Cell Biol 15: 3531-3539, 1995.
25. Schoderbek WE, Kim KE, Ridgway EC, Mellon PL and Maurer RA: Analysis of DNA sequences required for pituitary-specific expression of the glycoprotein hormone alpha-subunit gene. Mol Endocrinol 6: 893-903, 1992.
26. Schoderbek WE, Roberson MS and Maurer RA: Two different DNA elements mediate gonadotropin releasing hormone effects on expression of the glycoprotein hormone alpha-subunit gene. J Biol Chem 268: 3903-3910, 1993.
27. Levi NL, Hanoch T, Benard O, et al: Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol 12: 815-824, 1998.
28. Strahl BD, Huang HJ, Sebastian J, Ghosh BR and Miller WL: Transcriptional activation of the ovine follicle-stimulating hormone beta-subunit gene by gonadotropin-releasing hormone: involvement of two activating protein-1-binding sites and protein kinase C. Endocrinology 139: 4455-4465, 1998.
29. Maudsley S, Naor Z, Bonfil D, et al: Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the luteinizing hormone beta-subunit gene. Mol Endocrinol 21: 1216-1233, 2007.
30. Shah BH, Farshori MP and Catt KJ: Neuropeptide-induced transactivation of a neuronal epidermal growth factor receptor is mediated by metalloprotease-dependent formation of heparin-binding epidermal growth factor. J Biol Chem 279: 414-420, 2004.
31. Davidson L, Pawson AJ, Millar RP and Maudsley S: Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. J Biol Chem 279: 1980-1993, 2004.
32. Stanislaus D, Ponder S, Ji TH and Conn PM: Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins. Biol Reprod 59: 579-586, 1998.
33. Gründker C, Völker P and Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142: 2369-2380, 2001.
34. Krsmanovic LZ, Mores N, Navarro CE, Arora KK and Catt KJ: An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proc Natl Acad Sci USA 100: 2969-2974, 2003.
35. Knollman PE and Conn PM: Multiple G proteins compete for binding with the human gonadotropin releasing hormone receptor. Arch Biochem Biophys 477: 92-97, 2008.
36. Kraus S, Benard O, Naor Z and Seger R: c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem 278: 32618-32630, 2003.
37. Kraus S, Levy G, Hanoch T, Naor Z and Seger R: Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64: 5736-5744, 2004.
38. Cheung LW and Wong AS: Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 275: 5479-5495, 2008.
39. Peng C, Fan NC, Ligier M, Vaananen J and Leung PC: Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 135: 1740-1746, 1994.
40. Nathwani PS, Kang SK, Cheng KW, Choi KC and Leung PC: Regulation of gonadotropin-releasing hormone and its receptor gene expression by 17beta-estradiol in cultured human granulosa-luteal cells. Endocrinology 141: 1754-1763, 2000.
41. Choi JH, Gilks CB, Auersperg N and Leung PC: Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 91: 4562-4570, 2006.
42. Chiang CH, Cheng KW, Igarashi S, Nathwani PS and Leung PC: Hormonal regulation of estrogen receptor alpha and beta gene expression in human granulosa-luteal cells in vitro. J Clin Endocrinol Metab 85: 3828-3839, 2000.
43. Iwashita M, Evans MI and Catt KJ: Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 62: 127-133, 1986.
44. Lin LS, Roberts VJ and Yen SS: Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 80: 580-585, 1995.
45. Cheng KW, Nathwani PS and Leung PC: Regulation of human gonadotropin-releasing hormone receptor gene expression in placental cells. Endocrinology 141: 2340-2349, 2000.
46. Raga F, Casañ EM, Wen Y, Huang HY, Bonilla-Musoles F and Polan ML: Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab 84: 636-642, 1999.
47. Docherty AJ, O'Connell J, Crabbe T, Angal S and Murphy G: The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 10: 200-207, 1992.
48. Maudsley S, Davidson L, Pawson AJ, Freestone SH, López de Maturana R, Thomson AA and Millar RP: Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology 84: 285-300, 2006.
49. Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y and Levite M: The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8: 1421-1426, 2002.
50. Kakar SS, Grizzle WE and Neill JD: The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 106: 145-149, 1994.
51. Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG and Gallagher CJ: The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 56: 2059-2065, 1996.
52. Kang SK, Cheng KW, Ngan ES, Chow BK, Choi KC and Leung PC: Differential expression of human gonadotropin-releasing hormone receptor gene in pituitary and ovarian cells. Mol Cell Endocrinol 162: 157-166, 2000.
53. Tieva A, Stattin P, Wikstrom P, Bergh A and Damber JE: Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 47: 276-284, 2001.
54. Finch AR, Sedgley KR, Caunt CJ and McArdle CA: Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines. J Endocrinol 196: 353-367, 2008.
55. Wormald PJ, Eidne KA and Millar RP: Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab 61: 1190-1194, 1985.
56. Miller WR, Scott WN, Morris R, Fraser HM and Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231-233, 1985.
57. Srkalovic G, Wittliff JL and Schally AV: Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841-1846, 1990.
58. Emons G, Ortmann O, Becker M, et al: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993.
59. Eidne KA, Flanagan CA and Millar RP: Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989-991, 1985.
60. Everest H, Hislop JN, Harding T, Uney JB, Flynn A, Millar RP and McArdle CA: Signalling and antiproliferative effects mediated by GnRH receptor after expression in breast cancer cells using recombinant adenovirus. Endocrinology 142: 4663-4672, 2001.
61. Finch AR, Green L, Hislop JN, Kelly E and McArdle CA: Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells. J Clin Endocrinol Metab 89: 1823-1832, 2004.
62. Emons G, Ortmann O, Schulz KD and Schally AV: Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metabol 8: 355-362, 1997.
63. Pati D and Habibi HR: Inhibition of human hepatocarcinoma cell proliferation by mammalian and fish gonadotropin-releasing hormones. Endocrinology 136: 75-84, 1995.
64. Krebs LJ, Wang X, Nagy A, Schally AV, Prasad PN and Liebow C: A conjugate of doxorubicin and an analog of luteinizing hormone-releasing hormone shows increased efficacy against oral and laryngeal cancers. Oral Oncol 38: 657-663, 2002.
65. Fekete M, Zalatnai A, Comaru-Schally AM and Schally AV: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4: 521-528, 1989.
66. Szepeshazi K, Schally AV and Halmos G: LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 30: 1485-1492, 2007.
67. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur J Cancer 41: 2196-2202, 2005.
68. Sion-Vardi N, Kaneti J, Segal-Abramson T, Giat J, Levy J and Sharoni Y: Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol 148: 1568-1570, 1992.
69. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 11: 5549-5557, 2005.
70. Moretti RM, Montagnani MM, van Groeninghen JC and Limonta P: Locally expressed LHRH receptor mediate the oncostatic and antimetastastic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 87: 3791-3797, 2002.
71. Moretti RM, Monagnani Marelli M, van Groeninghen JC, Motta M and Limonta P: Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 10: 161-167, 2003.
72. Van Groeninghen JC, Kiesel L, Winkler D and Zwirner M: Effects of luteinising-hormone-releasing hormone on nervous-system tumours. Lancet 352: 372-373, 1998.
73. Fekete M, Zalatnai A and Schally AV: Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 45: 87-91, 1989.
74. Nagy A, Schally AV, Armatis P, et al: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93: 7269-7273, 1996.
75. Schally AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20: 1247-1262, 1999.
76. Schally AV and Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15: 300-310, 2004.
77. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J and Armatis P: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer 82: 909-917, 1998.
78. Gründker C and Emons G: Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 1: 65-71, 2003.
79. So WK, Cheng JC, Poon SL and Leung PC: Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275: 5496-5511, 2008.
80. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E and Motta M: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 76: 797-800, 1993.
81. Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH and Choi WS: Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 26: 259-264, 1998.
82. Limonta P, Moretti RM, Montagnani Marelli M, Dondi D, Parenti M and Motta M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140: 5250-5256, 1999.
83. Segal-Abramson T, Kitroser H, Levy J, Schally AV and Sharoni Y: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 89: 2336-2339, 1992.
84. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A and Counis R: The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 71: 595-599, 1997.
85. Limonta P, Moretti RM, Marelli MM and Motta M: The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 24: 279-295, 2003.
86. Volker P, Gründker C, Schmidt O, Schulz KD and Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186: 171-179, 2002.
87. Wilkinson SJ, Kucukmetin A, Cross P, et al: Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. Hum Pathol 39: 1197-1204, 2008.
88. Shibata S, Sato H, Ota H, Karube A, Takahashi O and Tanaka T: Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol Oncol 66: 217-221, 1997.
89. Emons G, Weiss S, Ortmann O, Gründker C and Schulz KD: LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 142: 665-670: 2000.
90. Imai A, Takagi H, Horibe S, Fuseya T and Tamaya T: Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 81: 3249-3253, 1996.
91. Imai A, Horibe S, Takagi A and Tamaya T: Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Am J Obstet Gynecol 176: 371-376, 1997.
92. Kimura A, Ohmichi M, Kurachi H, et al: Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59: 5133-5142, 1999.
93. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81: 3930-3937, 1996.
94. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K and Schally AV: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91: 7090-7094, 1994.
95. Kim KY, Choi KC, Auersperg N and Leung PC: Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13: 211-220, 2006.
96. Cheung LW, Leung PC and Wong AS: Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metallo-proteinase (MMP)-2 and MMP-9. Cancer Res 66: 10902-10910, 2006.
97. Qayum A, Gullick W, Clayton RC, Sikora K and Waxman J: The effects of Gonadotropin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62: 96-99, 1990.
98. Halmos G, Arencibia JM, Schally AV, Davis R and Bostwick DG: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 163: 623-629, 2000.
99. Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 14: 191-208, 1989.
100. Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212, 1992.
101. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095, 1994.
102. Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM and Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 38: 151-158, 1999.
103. Dondi D, Moretti RM, Montagnani Marelli M, et al: Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 76: 506-511, 1998.
104. Tieva A, Wilkström P, Olofsson JI, Bergh A and Damber JE: Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration. Prostate 39: 101-107, 1999.
105. Redding TW and Schally AV: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 78: 6509-6512, 1981.
106. Tolis G, Ackman D, Stellos A, et al: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79: 1658-1662, 1982.
107. Arencibia JM, Schally AV, Halmos G, Nagy A and Kiaris H: In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. Anticancer Drugs 12: 71-78, 2001.
108. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN and Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206: 205-213, 2005.
109. Gründker C, Huschmand Nia A and Emons G: Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol Cancer Ther 4: 225-231, 2005.
110. Montagnani Marelli M, Moretti RM, Dondi D and Motta M: Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 76: 506-511, 1999.
111. Maudsley S, Davidson L, Pawson AJ, Chan R, López de Maturana R and Millar RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 64: 7533-7544, 2004.
112. Maiti K, Oh DY, Moon JS, et al: Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J Clin Endocrinol Metab 90: 4287-4298, 2005.
113. Kraus S, Naor Z and Seger R: Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett 234: 109-123, 2006.
114. Enomoto M, Utsumi M and Park MK: Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 147: 530-542, 2006.
115. Dondi D, Festuccia C, Piccolella M, Bologna M and Motta M: GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 15: 393-400, 2006.
116. Yates C, Wells A and Turner T: Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 92: 366-375, 2005.
117. Blair HC, Wells A and Isales CM: Pituitary glycoprotein hormone receptors in non-endocrine organs. Trends Endocrinol Metabol 18: 227-233, 2007.
118. Fekete M, Wittliff JL and Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989.
119. Eidne KA, Flanagan CA, Harris NS and Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425-432, 1987.
120. Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM and Groot K: Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 85: 2608-2615, 1999.
121. Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM and Groot K: Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 59: 255-262, 2000.
122. Nagy A and Schally AV: Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 73: 851-859, 2005.
123. Fister S, Schlotawa L, Günthert AR, Emons G and Gründker C: Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells. Gynecol Endocrinol 24: 24-29, 2008.
124. Sedgley KR, Finch AR, Caunt CJ and McArdle CA: Intracellular gonadotropin-releasing receptors in breast cancer and gonadotrope linaje cells. J Endocrinol 191: 625-636, 2006.
125. Scott WN, Mullen P and Miller WR: Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone. Eur J Cancer 27: 1458-1461, 1991.
126. Hershkovitz E, Marbach M, Bosin E, et al: Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 77: 963-968, 1993.
127. Szepeshazi K, Milovanovic S, Lapis K, Groot K and Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181-192, 1992.
128. Gunthert AR, Gründker C, Olota A, Lasche J, Eicke N and Emons G: Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 153: 613-625, 2005.
129. Gründker C, Völker P, Schulz KD and Emons G: Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 78: 194-202, 2000.
130. Von Alten J, Fister S, Schulz H, Viereck V, Frosch KH, Emons G and Gründker C: GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 100: 13-21, 2006.
131. Navratil AM, Knoll JG, Whitesell JD, Tobet SA and Clay CM: Neuroendocrine plasticity in the anterior pituitary: GnRH mediated movement in vitro and in vivo. Endocrinology 148: 1736-1744, 2007.
132. Chou CS, Zhu H, Shalev E, MacCalman CD and Leung PC: The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. J Clin Endocrinol Metab 87: 5594-5603, 2002.
133. Dass K, Ahmad A, Azmi AS, Sarkar SH and Sarkar FH: Evolving role of uPA/ uPAR system in human cancers. Cancer Treat Rev 34: 122-136, 2008.
134. Chou CS, Zhu H, MacCalman CD and Leung PC: Regulatory effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the levels of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinases-1 in primary cultures of human extravillous cytotrophoblasts. J Clin Endocrinol Metab 88: 4781-7490, 2003.
135. Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F and Gudermann T: Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 278: 47307-47318, 2003.
136. Mareel M and Leroy A: Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83: 337-376, 2003.
137. Bagorda A and Parent CA: Eukaryotic chemotaxis at a glance. J Cell Sci 121: 2621-2624, 2008.
138. Aspenström P, Fransson A and Saras J: Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 377: 327-337, 2004.
139. Ridley A and Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399, 1992.
140. Ridley A, Paterson HF, Johnston CL, Diekmann D and Hall A: The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70: 401-410, 1992.
141. Kozma R, Ahmed S, Best A and Lim L: The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol Cell Biol 15: 1942-1952, 1995.
142. Geyer M and Wittinghofer A: GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. Curr Opinion Struct Biol 7: 786-792, 1997.